By Benjamin Chiou
Date: Thursday 02 May 2024
(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.
Interim analysis of the ECHO Phase III trial shows that Calquence, otherwise known as acalabrutinib - when used with a combination of standard-of-care chemoimmunotherapy,...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news